[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620776":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":67,"collaborators":18,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":18,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":18,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":28,"whyStopped":18,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Vanda Pharmaceuticals","INDUSTRY",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Ponesimod","EXPERIMENTAL",[12],"Drug: Ponesimod",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","Oral Tablet",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Vanda Pharmaceuticals, Inc.","CONTACT","202-734-3400","clinicaltrials@vandapharma.com",[26,40,49,58],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":18},"Vanda Investigational Site","RECRUITING","Glendale","Arizona","85308","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-112.18599,33.53865,{"lat":38,"lon":37},{"facility":27,"status":28,"city":41,"state":42,"zip":43,"country":32,"countryCode":33,"cosmosGeoPoint":44,"geoPoint":48,"contacts":18},"Fremont","California","94538",{"type":35,"coordinates":45},[46,47],-121.98857,37.54827,{"lat":47,"lon":46},{"facility":27,"status":28,"city":50,"state":51,"zip":52,"country":32,"countryCode":33,"cosmosGeoPoint":53,"geoPoint":57,"contacts":18},"Rochester","New York","14623",{"type":35,"coordinates":54},[55,56],-77.61556,43.15478,{"lat":56,"lon":55},{"facility":27,"status":28,"city":59,"state":60,"zip":61,"country":32,"countryCode":33,"cosmosGeoPoint":62,"geoPoint":66,"contacts":18},"Spokane","Washington","99202",{"type":35,"coordinates":63},[64,65],-117.42908,47.65966,{"lat":65,"lon":64},{"type":68,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100620776","phase-3-open-label-study-to-investigate-the-safety-and-efficacy-of-ponesimod-in-moderate-to-severe-chronic-plaque-psoriasis-100620776",false,"NCT07362017","Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis","A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis","Inclusion Criteria:\n\n* Male and female subjects aged 18-65 years, inclusive\n* BMI \\>18 and \\\u003C40\n* Minimum affected BSA of 10%\n* PASI score ≥ 12\n* PGA ≥ 3\n* Diagnosed with moderate-to-severe plaque psoriasis\n\nExclusion Criteria:\n\n* Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis\n* History of an allergic reaction or known and\u002For significant sensitivity to study drug","ALL","18 Years","65 Years",{"count":80,"type":81},300,"ESTIMATED","INTERVENTIONAL",[84],"PHASE3","An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis",[87],"Moderate-to-severe Chronic Plaque Psoriasis",[89,90],"psoriasis","Moderate-to-severe chronic plaque psoriasis","2026-06-10",{"date":93,"type":94},"2026-06-11","ACTUAL",{"date":96,"type":94},"2026-02-17",{"date":98,"type":81},"2028-12",{"name":5,"class":6},4]